Antibody-Drug Conjugates (ADCs) are highly toxic drugs which can, in small amounts, posing significant risks to human health. As such, their production and handling require specialized facilities to ensure the safety of operators and prevent cross-contamination. Without these tailored facilities, the manufacturing of ADCs can result in the release of hazardous substances into the environment. However, preventing such contamination often entails a considerable environmental footprint. Additionally, the production of HPAPIs, which are involved in ADCs, contributes to environmental impacts through high energy consumption and waste generation. This presentation examines ADC production processes with regard to the generation of highly potent waste and wastewater streams, and highlights avoidance strategies within production. Furthermore, safe, efficient, and resource-conserving treatment options are evaluated for their applicability. Case studies and practical examples demonstrate how these methods are implemented in industrial settings.